IDEAS home Printed from https://ideas.repec.org/a/sae/sagope/v4y2014i1p2158244014527986.html
   My bibliography  Save this article

Formulation of a Success Model in Pharmaceutical R&D

Author

Listed:
  • Hyunju Rachel Kim

Abstract

Recently, pharmaceutical R&D has been demanded to increase productivity in terms of time efficiency and innovation as well. There have been discontinuous challenges coming up in this industry, such as globalized R&D competition, stricter regulation, lengthy process of clinical trials, and so on. Considering external changes, high competition, and discontinuities in the industry, it is a good time to redefine the concept of success in pharmaceutical R&D. Thus, this article attempts to formulate a new success model in pharmaceutical R&D, through contextualizing the industry’s success factors.

Suggested Citation

  • Hyunju Rachel Kim, 2014. "Formulation of a Success Model in Pharmaceutical R&D," SAGE Open, , vol. 4(1), pages 21582440145, March.
    • Handle: RePEc:sae:sagope:v:4:y:2014:i:1:p:2158244014527986
    DOI: 10.1177/2158244014527986
    as

    Download full text from publisher

    File URL: https://journals.sagepub.com/doi/10.1177/2158244014527986
    Download Restriction: no
    File URL: https://libkey.io/10.1177/2158244014527986?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Weijan Shan & Gordon Walker & Bruce Kogut, 1994. "Interfirm cooperation and startup innovation in the biotechnology industry," Strategic Management Journal, Wiley Blackwell, vol. 15(5), pages 387-394, June.
    2. H. Igor Ansoff, 1987. "The emerging paradigm of strategic behavior," Strategic Management Journal, Wiley Blackwell, vol. 8(6), pages 501-515, November.
    3. Zucker, Lynne G. & Darby, Michael R., 1997. "Present at the biotechnological revolution: transformation of technological identity for a large incumbent pharmaceutical firm," Research Policy, Elsevier, vol. 26(4-5), pages 429-446, December.
    4. Orsenigo, L. & Pammolli, F. & Riccaboni, Massimo, 2001. "Technological change and network dynamics: Lessons from the pharmaceutical industry," Research Policy, Elsevier, vol. 30(3), pages 485-508, March.
    5. Chan, Su Han & Martin, John D. & Kensinger, John W., 1990. "Corporate research and development expenditures and share value," Journal of Financial Economics, Elsevier, vol. 26(2), pages 255-276, August.
    6. C. K. Prahalad & Richard A. Bettis, 1986. "The dominant logic: A new linkage between diversity and performance," Strategic Management Journal, Wiley Blackwell, vol. 7(6), pages 485-501, November.
    7. Gary P. Pisano, 1994. "Knowledge, Integration, and the Locus of Learning: An Empirical Analysis of Process Development," Strategic Management Journal, Wiley Blackwell, vol. 15(S1), pages 85-100, December.
    8. Luigi Orsenigo & Fabio Pammolli & Massimo Riccaboni & Andrea Bonaccorsi & Giuseppe Turchetti, 1997. "The Evolution of Knowledge and the Dynamics of an Industry Network," Journal of Management & Governance, Springer;Accademia Italiana di Economia Aziendale (AIDEA), vol. 1(2), pages 147-175, June.
    9. Scherer, Frederic Michael, 2011. "R&D Costs and Productivity in Biopharmaceuticals," Scholarly Articles 5688848, Harvard Kennedy School of Government.
    10. Light, Donald W. & Warburton, Rebecca N., 2005. "Setting the record straight in the reply by DiMasi, Hansen and Grabowski," Journal of Health Economics, Elsevier, vol. 24(5), pages 1045-1048, September.
    11. Yu-Ting Cheng & Andrew H. Van de Ven, 1996. "Learning the Innovation Journey: Order out of Chaos?," Organization Science, INFORMS, vol. 7(6), pages 593-614, December.
    12. James P. Walsh, 1995. "Managerial and Organizational Cognition: Notes from a Trip Down Memory Lane," Organization Science, INFORMS, vol. 6(3), pages 280-321, June.
    13. Thomas A. Abbott & John A. Vernon, 2007. "The cost of US pharmaceutical price regulation: a financial simulation model of R&D decisions," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 293-306.
    14. David J. Teece & Gary Pisano & Amy Shuen, 1997. "Dynamic capabilities and strategic management," Strategic Management Journal, Wiley Blackwell, vol. 18(7), pages 509-533, August.
    15. Trochim, W.M. & Cabrera, D.A. & Milstein, B. & Gallagher, R.S. & Leischow, S.J., 2006. "Practical challenges of systems thinking and modeling in public health," American Journal of Public Health, American Public Health Association, vol. 96(3), pages 538-546.
    16. Scherer, F. M., 2011. "R&D Costs and Productivity in Biopharmaceuticals," Working Paper Series rwp11-046, Harvard University, John F. Kennedy School of Government.
    17. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Tobias Basse & Christoph Schwarzbach & J.-Matthias Schulenburg, 2023. "Dividend policy issues in the European pharmaceutical industry: new empirical evidence," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(5), pages 803-816, July.
    2. Angelo Kenneth S. Romasanta & Peter Sijde & Jacqueline Muijlwijk-Koezen, 2020. "Innovation in pharmaceutical R&D: mapping the research landscape," Scientometrics, Springer;Akadémiai Kiadó, vol. 125(3), pages 1801-1832, December.
    3. Ng, Desmond W., 2011. "Thinking Outside the Box: An Absorptive Capacity Approach to the Product Development Process," International Food and Agribusiness Management Review, International Food and Agribusiness Management Association, vol. 14(3), pages 1-28, September.
    4. Filipe M. Santos & Kathleen M. Eisenhardt, 2005. "Organizational Boundaries and Theories of Organization," Organization Science, INFORMS, vol. 16(5), pages 491-508, October.
    5. Zhang, Jing & Baden-Fuller, Charles & Mangematin, Vincent, 2007. "Technological knowledge base, R&D organization structure and alliance formation: Evidence from the biopharmaceutical industry," Research Policy, Elsevier, vol. 36(4), pages 515-528, May.
    6. Billette de Villemeur, Etienne & Versaevel, Bruno, 2019. "One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry," Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
    7. Bruce Rasmussen, 2010. "Innovation and Commercialisation in the Biopharmaceutical Industry," Books, Edward Elgar Publishing, number 13680.
    8. Haeussler, Carolin & Patzelt, Holger & Zahra, Shaker A., 2012. "Strategic alliances and product development in high technology new firms: The moderating effect of technological capabilities," Journal of Business Venturing, Elsevier, vol. 27(2), pages 217-233.
    9. Henk W. Volberda & Nicolai J. Foss & Marjorie A. Lyles, 2010. "PERSPECTIVE---Absorbing the Concept of Absorptive Capacity: How to Realize Its Potential in the Organization Field," Organization Science, INFORMS, vol. 21(4), pages 931-951, August.
    10. Frank T. Rothaermel & Andrew M. Hess, 2007. "Building Dynamic Capabilities: Innovation Driven by Individual-, Firm-, and Network-Level Effects," Organization Science, INFORMS, vol. 18(6), pages 898-921, December.
    11. Shilpi Tyagi & D. K. Nauriyal & Rachita Gulati, 2018. "Firm level R&D intensity: evidence from Indian drugs and pharmaceutical industry," Review of Managerial Science, Springer, vol. 12(1), pages 167-202, January.
    12. Wu, Lei-Yu, 2007. "Entrepreneurial resources, dynamic capabilities and start-up performance of Taiwan's high-tech firms," Journal of Business Research, Elsevier, vol. 60(5), pages 549-555, May.
    13. Ilgaz Arikan & Ipek Koparan & Asli M Arikan & Oded Shenkar, 2022. "Dynamic capabilities and internationalization of authentic firms: Role of heritage assets, administrative heritage, and signature processes," Journal of International Business Studies, Palgrave Macmillan;Academy of International Business, vol. 53(4), pages 601-635, June.
    14. Gilsing, Victor & Nooteboom, Bart, 2006. "Exploration and exploitation in innovation systems: The case of pharmaceutical biotechnology," Research Policy, Elsevier, vol. 35(1), pages 1-23, February.
    15. Samina Karim, 2009. "Business Unit Reorganization and Innovation in New Product Markets," Management Science, INFORMS, vol. 55(7), pages 1237-1254, July.
    16. Jing Zhang & Charles Baden-Fuller & Vincent Mangematin, 2007. "Technological Knowledge Base, R&D Organization Structure and Alliance Formation: Evidence from the Biopharmaceutical Industry," Post-Print hal-00424512, HAL.
    17. Paul A. Pavlou & Omar A. El Sawy, 2010. "The “Third Hand”: IT-Enabled Competitive Advantage in Turbulence Through Improvisational Capabilities," Information Systems Research, INFORMS, vol. 21(3), pages 443-471, September.
    18. Chang, Shao-Chi & Chen, Sheng-Syan & Lai, Jung-Ho, 2008. "The effect of alliance experience and intellectual capital on the value creation of international strategic alliances," Omega, Elsevier, vol. 36(2), pages 298-316, April.
    19. Jonathan R. Clark & Venkat Kuppuswamy & Bradley R. Staats, 2018. "Goal Relatedness and Learning: Evidence from Hospitals," Organization Science, INFORMS, vol. 29(1), pages 100-117, February.
    20. Kim, Jongwook & Mahoney, Joseph T., 2008. "A Strategic Theory of the Firm as a Nexus of Incomplete Contracts: A Property Rights Approach," Working Papers 08-0108, University of Illinois at Urbana-Champaign, College of Business.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:sae:sagope:v:4:y:2014:i:1:p:2158244014527986. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: SAGE Publications (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.